-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 GLsdSvPgGKoMqCTjKOJA5GJEGgWUrDu/cnAS0ydVGQ0n9f/Dmj0Ibqx2ytFNhaK1
 MeEV+Dr/7pgCCTx93wYR2Q==

<SEC-DOCUMENT>0001129928-09-000015.txt : 20090325
<SEC-HEADER>0001129928-09-000015.hdr.sgml : 20090325
<ACCEPTANCE-DATETIME>20090325165514
ACCESSION NUMBER:		0001129928-09-000015
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20090325
FILED AS OF DATE:		20090325
DATE AS OF CHANGE:		20090325

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		09704515

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form61-k.htm
<TEXT>
<html>
  <head>
    <title>form61-k.htm</title>
<!-- Licensed to: Oncolytics Biotech Inc.-->
<!-- Document Created using EDGARizer 4.0.7.0 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div>&#160;</div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div><br>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECURITIES
AND EXCHANGE COMMISSION</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Washington,
D.C. 20549</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">Form
6-K</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Report
of Foreign Private Issuer</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to Rule&#160;13a-16 or 15d-16</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of
the Securities Exchange Act of 1934</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the
month of&#160;March 2009</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
File Number 000-31062</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">Oncolytics
Biotech Inc.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">(Translation
of registrant&#8217;s name into English)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Suite&#160;210,
1167 Kensington Crescent NW</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Calgary,
Alberta, Canada T2N 1X7</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">(Address
of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether the registrant files or will file annual reports under
cover Form&#160;20-F or Form&#160;40-F.</font></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td valign="top" width="38%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form&#160;20-F&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#254;</font></font></div>
            </td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="38%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form&#160;40-F&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form&#160;6-K in paper as
permitted by Regulation&#160;S-T Rule&#160;101(b)(1):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T
Rule&#160;101(b)(1) only permits the submission in paper of a Form&#160;6-K if
submitted solely to provide an attached annual report to security
holders.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form&#160;6-K in paper as
permitted by Regulation&#160;S-T Rule&#160;101(b)(7):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T
Rule&#160;101(b)(7) only permits the submission in paper of a Form&#160;6-K if
submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on
which the registrant&#8217;s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant&#8217;s security holders, and, if discussing a material
event, has already been the subject of a Form&#160;6-K submission or other
Commission filing on EDGAR.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether by furnishing the information contained in this Form, the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td valign="top" width="38%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Yes&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
            </td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="38%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">No&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#254;</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If &#8220;Yes&#8221;
is marked, indicate below the file number assigned to the registrant in
connection with Rule&#160;12g3-2(b):&#160;&#160;&#160;82&#160;-&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">EXHIBIT</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NUMBER</font></div>
            </td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="69%" style="BORDER-BOTTOM: black 4px double">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">DESCRIPTION</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="69%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td valign="top" width="7%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99.1</font></div>
            </td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="69%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">News Release Dated March 25, 2009
      -&#160;</font>Oncolytics Biotech<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">&#174;</font>
      Inc. Completes Enrolment in Combination REOLYSIN<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">&#174;</font>/Gemcitabine
      Trial</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SIGNATURES</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" colspan="3" valign="top" width="39%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Oncolytics
      Biotech Inc.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Registrant)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="middle" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="middle" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td align="left" valign="middle" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="middle" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td align="left" valign="top" width="38%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date:&#160;&#160;March
      25, 2009</font></div>
            </td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="2%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
            </td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="36%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/&#160;&#160;Matt
      Coffey</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Matt
      Coffey</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief
      Operating Officer</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><br></body>
</html>




</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<TEXT>
<html>
  <head>
    <title>ex991.htm</title>
<!-- Licensed to: Oncolytics Biotech Inc.-->
<!-- Document Created using EDGARizer 4.0.7.0 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div><img src="ex9910.jpg" alt=""><br>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">210, 1167
Kensington Cr. N.W</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Calgary,
Alberta</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Canada
T2N 1X7</font></div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;F</font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">OR
IMMEDIATE RELEASE</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br><br>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Oncolytics
Biotech&#174; Inc. Completes Enrolment in</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Combination
REOLYSIN&#174;/Gemcitabine Trial</font></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">CALGARY, AB, --- </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">March 25</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">, 200</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">9</font> - Oncolytics Biotech Inc.
(&#8220;Oncolytics&#8221;) (TSX:ONC, NASDAQ:ONCY) today announced the completion
of&#160;patient enrolment in its U.K. clinical trial to evaluate the anti-tumour
effects of intravenous administration of REOLYSIN&#174; in combination with
gemcitabine (Gemzar&#174;) in patients with advanced cancers including breast, and
head and neck.&#160;&#160;The principal investigators are Dr. Johann de Bono of
The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research,
U.K., and Professor Jeff Evans of the University of Glasgow,
Scotland.</font></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A total
of 15 patients were enrolled in the trial.&#160;&#160;Of the ten patients
evaluable for response, two patients (breast and nasopharyngeal) had partial
responses (PRs) and five patients had SD (stable disease) for 4-8 cycles, for a
total disease control rate (CR (Complete response)+PR +SD) of 70%.</font></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;The
results to date using this treatment combination in late-stage cancer patients
indicate that further studies using this drug combination are warranted,&#8221; said
Dr. Brad Thompson, President and CEO of Oncolytics. &#8220;We plan to initiate further
studies in the U.S. using a modified dosage regime of REOLYSIN and the commonly
used U.S. dosage of gemcitabine (800 mg/m2) in patients with advanced or
metastatic pancreatic cancer in partnership with the Cancer Therapy &amp;
Research Center at The University of Texas Health Science Center in San Antonio,
(CTRC at UTHSCSA).&#8221;</font></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The U.K.
trial (REO 009) is an open-label, dose-escalating, non-randomized study of
REOLYSIN given intravenously with gemcitabine every three
weeks.&#160;&#160;Gemcitabine (1000&#160;mg/m2) was administered to patients in
combination with escalating dosages of REOLYSIN intravenously.</font></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Eligible
patients included those who had been diagnosed with advanced or metastatic solid
tumours including pancreatic, lung and ovarian cancers that are refractory (have
not responded) to standard therapy or for which no curative standard therapy
exists.</font></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
primary objective of the trial was to determine the Maximum Tolerated Dose
(MTD), Dose-Limiting Toxicity (DLT), recommended dose and dosing schedule and
safety profile of REOLYSIN when administered in combination with
gemcitabine.&#160;&#160;Secondary objectives include the evaluation of immune
response to the drug combination, the body&#8217;s response to the drug combination
compared to chemotherapy alone and any evidence of anti-tumour
activity.</font></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">About
Oncolytics Biotech Inc.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Oncolytics
is a Calgary-based biotechnology company focused on the development of oncolytic
viruses as potential cancer therapeutics.&#160;&#160;Oncolytics&#8217; clinical
program includes a variety of Phase I/II and Phase II human trials using
REOLYSIN, its proprietary formulation of the human reovirus, alone and in
combination with radiation or chemotherapy.&#160;&#160;For further information
about Oncolytics, please visit <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.oncolyticsbiotech.com</font></font></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Gemzar<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">&#174;</font> is
indicated for NSCLC, breast, pancreatic and ovarian cancer.&#160;&#160;For more
information about Gemzar<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">&#174;</font>, please
visit <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.gemzar.com</font>.</font></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">This
press release contains forward-looking statements, within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended. Forward-looking
statements, including the Company&#8217;s expectations related to the U.K. and U.S.
combination REOLYSIN/gemcitabine clinical trials and the Company&#8217;s belief as to
the potential of REOLYSIN as a cancer therapeutic, involve known and unknown
risks and uncertainties, which could cause the Company&#8217;s actual results to
differ materially from those in the forward-looking statements. Such risks and
uncertainties include, among others, the availability of funds and resources to
pursue research and development projects, the efficacy of REOLYSIN as a cancer
treatment, the tolerability of REOLYSIN outside a controlled test, the success
and timely completion of clinical studies and trials, the Company&#8217;s ability to
successfully commercialize REOLYSIN, uncertainties related to the research and
development of pharmaceuticals and uncertainties related to the regulatory
process. Investors should consult the Company&#8217;s quarterly and annual filings
with the Canadian and U.S. securities commissions for additional information on
risks and uncertainties relating to the forward-looking statements. Investors
are cautioned against placing undue reliance on forward-looking statements. The
Company does not undertake to update these forward-looking statements, except as
required by applicable laws.</font></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FOR
FURTHER INFORMATION PLEASE CONTACT:</font></div>
        <div>
          <table cellpadding="0" cellspacing="0" width="100%">
              <tr>
                <td align="left" valign="top" width="25%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Oncolytics
      Biotech Inc.</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cathy
      Ward</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">210,
      1167 Kensington Cr NW</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Calgary,
      Alberta T2N 1X7</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Tel:
      403.670.7377</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fax:
      403.283.0858</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">cathy.ward@oncolytics.ca</font></font></div>
                  <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
                </td>
                <td align="left" valign="top" width="26%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The
      Equicom Group</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nick
      Hurst</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">325,
      300 5th Ave. SW</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Calgary,
      AB, T2P 3C4</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Tel:
      403.538.4845</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fax:
      403.237.6916</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">nhurst</font><font style="DISPLAY: inline">@equicomgroup.com</font></font></div>
                  <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
                </td>
                <td align="left" valign="top" width="28%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The
      Investor Relations Group</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Erika
      Moran</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11
      Stone St, 3rd Floor</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">New
      York, NY&#160;&#160;10004</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Tel:&#160;&#160;212.825.3210</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fax:&#160;&#160;212.825.3229</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">emoran@investorrelationsgroup.com</font></font></div>
                </td>
              </tr>
          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-30-</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      </div>
    </div>
  </body>
</html>




</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex9910.jpg
<TEXT>
begin 644 ex9910.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@```#$!`@`0````3@``````
M``!@`````0```&`````!````4&%I;G0N3D54('8T+C`P`/_;`$,``@$!`0$!
M`@$!`0("`@("!`,"`@("!00$`P0&!08&!@4&!@8'"0@&!PD'!@8("P@)"@H*
M"@H&"`L,"PH,"0H*"O_;`$,!`@("`@("!0,#!0H'!@<*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"O_``!$(`%$!
M4P,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/W\HHK+\9^,_#'P]\,WOC/QIKUII>E:;;M/?ZA>S!(H8QU8D_RZ
MDD`<FDW8#1>9%&<YK$\;?%#X>?#73UU7XA^.-(T.V9E5;C5M2BMD))P!F1@.
M37P+\:?^"G/[0W[1OQ-N/@3_`,$__!$T\9D:-/$XM`]Q<(,!ID$H$5K%UP\F
M21@C:>"SX>?\$8/B-\4-03QQ^UU^T'?7.H7`,EW9Z7.UW<JS;\J;JXW*"/E/
MRH1G(R?O'SY8V567+AX<WGLC14[?$['U(W_!3']A)',;_M'Z)D$CB&<^W_/*
MMKP/^W=^Q[\2=4_L;P?^T)X:N+HNB)#/>_9C(SMM54\X)O8GC:N37E=C_P`$
M8?V'X+&&WN_#WB"YECB59+F3Q).K2D#EB$(4$GG``'/`K#^)7_!$;]E#Q+H@
MM_`.K^(O#%\F[9=KJ!O8WR`,/'-U`Y^ZRGGJ>E+GS)?9C][$U2?<^QK+4;+4
M;=;NRNHY8G&4EB<,K#V(X/X5,&5NAS7Y7^._V;_V\?\`@F/K'_"R?@MX^N?$
MO@NWD#7B6B2/;I"'7"7=FQ(13N(\R(Y&6.Y,\_5O[#'_``4T^&/[5\4/@CQ+
M!%X=\<%';^Q'D9H;U4QF2VD(`8X.3&?G`4G!`W5I2QT)5/9U$XR\^OH$J;2N
MM3ZDHI$;<H;'44M=Q`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`#96`4[B`,<DG
MI7Y@_M:?&+XG_P#!33]I>#]D?]GV5[;POH%Y-_:-_+=8M[HQ2*DE]*JGF*,\
M1)R69\XR1M^N/^"FW[0NH?L\?LG:WKGAV]^SZUKCKHVCR@L&CDG!#R*5'#)$
M)&!XY4<UQO\`P1[_`&;[#X1_LPV_Q-U&TQK?CHK?SRNF&CLURMO&/]DKF7/\
M7F@GH,>9BF\366'CMO+T[&L;07,>W_LQ_LM_"O\`93^'<?P_^&&CK&)2)=4U
M&7+7%_/C!ED<DGV5<[5'`KTN@#`Q17HPA&G%1BK)&3;;NPHHHJ@&RQ+,A1L8
M(P01G-?GY_P4R_X)X>'_``GX:D_:E_9>T"70M<T*[6^UJPT-FC!A7&;JWC08
MBDC/[QBN`5#,1D<_H+4-_9VM_;/97MO'-#*C)+#*@974C!4@]00<8KGQ-"%>
M'*]^C[#BW%W1\W_\$U/VT%_:U^#[6_BIBOBWPRD-KX@+%!]MW*?+O$"@`*^&
MR,8#!ATQ7TM7Y8^,O!K_`/!-O_@IYX=U#P1.T/A'Q;<QLEDA5MMC=S>3-;E`
M5P(Y@&3H`%09.&!_4N)MV>.AK#`5IU(.G/XHNS*J12=UU'T445WD!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110!^='_!=?6)[_6?A;\-I(D6TNYK^Y>=`?,5MUO#@=L8D
M)Z=0.W%?H'X+\-:=X,\):;X3TE0+;3;"&U@^15^1$"CA0`.!V`%?GQ_P70T^
M_L/&?PJ\;7-MMTVW-]!-<!P=K^9;R8V_>/RHQX';'7`/Z'^'M6LM=T2TUK39
M2]M=VT<UO(5(W(RAE.#R.#TKS<,D\=6;\OR-)_!$N4445Z1F%%%%`!1110!\
M`?\`!>;PAHTGPQ\">/6@(U*#7Y]/CF7`_<20-*RGC)PT*D<\9;^\:^SOV>]:
MU3Q+\"_!OB37+QKB\O\`PIIT]W,R@&21[:-F;"@`9)/0"OCS_@O%K&FQ_!?P
M-H4EX@O)O%4MQ%;[OF>*.UD1W`[A6DC!]W%?7G[-D%U8?L]^!;"^M)(9H?!V
MF)+#,A1T86T8*LI&5((Y!KSZ7^_U?1?J5_R[B>/?\%1?VG_BO^RG\$M%\>?"
M*YT^'4+_`,41V$[ZC9>>GDM;SR$!<C!W1KSZ9KSO]A__`(*;>)?&_CH?`?\`
M:XMK#1?$VH>5/X;UFVB$%GJ4<R"2&,\E075E:.0$K(&`X;&Y_P#P78_Y-?\`
M"_\`V/</_I'=U0\??\$]O"W[7/[$?PT\8^$#;Z1X]TKX>Z6-+U/[B7R+:H5M
MK@CMG[DG5">ZY%85GB?KDG3=[+;OY%+E<+,^COVU?B1\2?A#^S'XL^*'PJU2
MPM=9T'3Q>Q2ZE:>=$T:2*9$V9&69-P!)X)%<K_P32_:(^)G[3_[-Q^)WQ9N[
M&;53K]W9[M/LO(C\J,1E?ER><L>:^-[#]NGX@77[+'Q-_8M_:LL+VT\::7X8
MN[72-2U'B6Z\I0WV:<L?FE"+E)`2)1CDG!;Z0_X(F+N_8I7G_F;=0_E%54L5
M[?%QY6[6=UYI@X*$+-'U9XD\3:#X-T2\\2^*-5M['3["V>>]O+J4)%#&HRS,
MQX``%?'%E^W?^T[^V#XQU#P=^P1\-M+M-$T>ZV:CX]\9,WD-AAA4A494NOS*
M#N8C.1'C->D_\%6?"7CWQK^Q3XJTCX?12S30M:W6HV=O;&62YLXIU>5%`!/&
M!(2.<1FO-/\`@B/\0?AE=?LX7GPYT76XE\3VNNW5[K&F3WBF:2-_+6.X2,<K
M$5")G^^K'/(K2M4F\4J*?*FK_P##,2BE&YW-U\-_^"K-B9]3M/VC/A=>R^4#
M%I\GA*>.)V7<0H;<2F[(!8[L``@<'/MWP/E^.-QX,2Z_:!M_#,.OR3.9+;PI
MY[6L,><*N^9BTC'DDX4#.`.,GKXQO7=TIP^0_6NJE14'>[^;N2W<\[_:;_:6
M^&O[+'PRN?B9\2M2*1(/+T[3X2#<:C<D96")3U8X))/"J"QX%?/7PA^,W_!2
M;]KG0[?XL_"ZQ\"?#7PC>V^='BU^VEU*YOL-@R?*4*J2&P2JY&"`00QY'_@N
MWX$\7:O\+O!?CG2I+V32-)UBXAU6W@@+0PO-&HBN)&!PI!4Q@D=9>"#@'Z3_
M`&!/B%X-^)7[(_@;6O!-O;6UM:>'X+"YL+5N+2X@01RQ$8&#N4GIR&!&003Q
M.I.KC94Y-I)77G_PQ25J:9YSXMTS_@K#\/-&D\6Z7X\^&?C>2SP[>&;?0)K.
M6\4Y!"2M*`"N0V,C=MP#G`.C^Q)_P4H^'W[6VMS?#G5/"=YX8\8VEF\T^DW,
MHE@N%0JLGDR<$E2>490P`SR`<?2MPVU\GIC)/I7Y/_L?6[?$+_@KIJ7B?X5W
M$MMI$7B;6[^XF@F:9)K0^:KDR*H&R61PRAOE^95YXI5IU,/5IQA)M2=K/4<4
MI)M]#]948.NX5\9_\$ZOVT_CM^TM^T)\1?AU\4M0TJ33/#4<ITM+#3!"Z[;Q
MX1N;<=WR@?CS7V7&/EW>M?FW_P`$;3C]L#XR?]<I_P#TY25OB9SCB:23T;=_
M/0E6Y6?I-5+Q%9:MJ&AW=EH6LC3[V6W=;6^-LLWD2$':^QL!\'!VDC/2KC-M
M[4,NX8KN)/@.V_X*(_M-_LK?M+O\'_V\=*TR;PY>X&G>)-`TEH8Q&7PMVF&;
MS8N0)$^_'R<''S?9OCOXX_"OX;_"JX^-/BWQG90>&H;);I=42821SQL`4\K;
MGS"^0%"Y+$@"L']J;]EGX8_M6_#.;X=?$>R*E=TNE:K;HOVC3;C&!-$Q_(J>
M&'![8_,?]EK]G'QM^T5^T;+^P[\4OC%J,W@OX;:EJ5W+I]M*PCG\BY2WD6$$
MGRO,9N"<^6K/M`+9KR*E3$X6?);FYOA?9^?D7925UT/K;]DW]J7]LC]M7XQW
M_CGP7IFF^$O@_IM_Y:37^D^=>W^P_P"ICD+X,C=78`I$#M&YA7TQ\==(^.VN
M^"TLOV??&6A:%KPO8V:]\0::]W;F`!MZ;$8'<25(.>Q]:Z/P3X)\+?#KPM8>
M"?!.B6VFZ3IELMO86-I$$CAC4<``?J>I/)R:U:[J5&:IVG)MO5_\#R);UN?%
MO[27B_\`X*:?LS?!C6?C7X@^.WPWU.ST983-96?@^999/,FCB&TM)@8,F>?2
MH/V7?'__``4R_:E^#6F_&GPS\<_AOI5GJ4UQ''97_@Z5Y4,4[Q$DK)CDH2,=
MC7IW_!5[_DPSQW_USL/_`$OMZSO^"0W_`"85X3/_`$_ZI_Z7SUR<C6-]GS.W
M+?<O[%SUW]GSP]^T-X>\-7L?[1_Q!T+Q!JTMYNLY?#VE-:00VX484AB69]VX
MD].F*\L_X*>_M+?%3]E?X"Z=\1/A'<V$.I7/B>WL)6U&R^T1F%X9W.%R.<QK
MS7TBJ[>]?&'_``7*;/[)6BG_`*GJT_\`26[K7%RE2P<G%ZI$P^(]Q_87^+_C
M7X]_LL>%/BY\1+BUEUG68+A[U[.V\J(E+J:-=J9./E1>_:MS]I7]I#X:?LM_
M#2[^*/Q-U4Q6T)\NRL8<&XO[@J2L$2D_,QP>>B@$D@"O/?\`@E;_`,F&^`/^
MO6\_]+KBO!_^"[O@OXA:Q\-O!?C#0K:YF\/Z1J5TNL^3N9()Y4C6":10,!<"
M5`Q(P9`!]ZI=:=/+_:+5V!1]ZQU'PS_:1_X*+?MCK!XT^`GPZ\+_``Y\&NQ^
MS:MXQ22]EU)"6Q)&B!=RC:!P`,MP[XP.\/A;_@JOX8/]KP?$_P"$WBAE^7^R
M+K1;NQ1\\;_.1F((ZXQSBNU_8*\5?#;Q5^R9X'E^%MY$^GV/ARULYK=9MSVU
MQ'&%FBD&YBK"0/D$]Z]DJZ-'VM)2<V[]GH'-9V,GP/'XRC\+6(^(4^G2:U]F
M4ZDVDQNEMYI&6$0D9FVCH"QR<9XS@?*7[;/_``4D\8?`KX_Z+^S)\'?AUINH
M>(=2DLEFU+Q'=R1V:&[D\N)%$7S'DY9R1M[*W4?8=>5_M(?L?_`#]JG3(]+^
M+W@B&\NH(3'9:Q:2>3>VBDDX25>=N<G:V4)Z@UKB(5G2M2=F)-)W9YA-\+/^
M"I&K7D/B!OVH_AWISQ9>+1[/PA)):RA\;DE=SO?RQ]QE*Y/WNM=-\#W_`."B
M%MXTL]%^/\/PQN?#T+S_`-H:SH<MVM]<#Y_*"0D"-"24SDG@'J37DTO_``3,
M_:/^&MO(G[.'[?WC'3((WADMM+U]WFA,B[0=[(^W9M4`)Y1&!@Y!KSO0/V_O
MVTOV9?VF-._9?_:/M?#_`(YDNM4M+:2^T5%%V8KF1@DB^2%7<-RDQO&I"IQG
M<&/%[3V#3J*2N[;W3;+4>?8_1JBBBO6,SY6_X*Y_`:Y^,?[)5]KVCZ6USJO@
M^[75[94`+M;J"MRHX)V^42Y`QGRAS6I_P2I_:`L?CA^R7HMC>:KYVM>$D71M
M81VR_P"['[B0Y))#1;/F/5E?TP/H^_M+>^M)+2[A62*5"DL;KE74C!!'<&OR
MU\5V/Q'_`."/_P"UTWC30]-;5?AQXQFF$%A;RE5>T#AS`1PJW-ON.PGAD)'&
MYMOEXA_5JZK_`&7H_+L_0TC[T7$_5#(/0T5S/PG^+'@+XU^";+XA_#;Q%:ZI
MI5_'NBN+697V-_%&^"=KJ>&4\@UTU>E&2DKK8S"BBBJ`*0LJ]3BACM4MBODW
M_@H__P`%$-$_9B\(R?#_`.&6JZ??^/\`4,PK;+,)#HT;)G[3*@S\QR`B-C).
M>0I!RK5H4*;G(:3D[(^;OVRM9@_;J_X*5^&/V?O",4EYHGAF\CTS4YXF9HV"
M2>=?2X#J`%0&+<""2N`22M?I]9VR6D"V\2;5C0*@!Z`=*^.O^"3_`.Q-J'P1
M\'3_`!^^*MLY\9^+[;S(X[D2>=I]G(1)LD#\B:1L.Y(R.%SP<_9=<F!I5.65
M2IO)_AT*FTW9=#R#]L;]D'PG^V9\/]/^'/C/Q3J>CVVG:PFHQ7&E"(R.ZQ2Q
M;3YBL-N)2>F>!7>?"3X>6'PD^&>@?"[2K^:ZM?#VC6VGV]S<A?,E2&-8PS;0
M!N(7)P`.:^4?VY_^"A_QL_9V_;M^$_['/PO\*Z5+9_$/P?K.M7^NS^#M5U^[
MLWL2@6.*QTV199%?<<OSMZGBNL_X)Y_\%"KG]K7QG\2_@G\0_#MIHGC;X9Z\
MEG>6)L[O3;C4[*6-9(=0_LV]07-E$X=5`D9PQ#%7X('8J4%/GZD'3?M@?\$\
M/@G^V->6.O\`BV6]T77+#$8UW11&)KB#G$,H=65U!.5)&Y>QP2*Z_P#9%_9=
M\,?LA_";_A4GA'Q)J&JV?]J3WPNM36,2[I=N5_=JJX&T8XS7J!.!FOFW]I?]
MN3Q%\$/V]/V=_P!CC1?`EE>VGQHE\2-JNN7-TXDTZ+2]/%PJQ1J,,SNZ@LQP
M%4X!)!$K#THU?:)>\-MM69](&)2"&P<C'(KYG^*G_!*_]G;QUXN;XD?#Z]US
MX>>(I)"\FI^";_[*KL6#.WE8*@L0<[=H.22">:^FJ\3_`."AG[8B_L%_LF>*
M?VHG^$^L>-/^$<@C8:)H[+'DNZH)9YF!6VMD+!I9R"(T!8@XJJE*%56D@3:V
M.8M?V"?B<+J-M3_;\^,EW;!Q]HMCK-NGFID;EW+%E<C(R.1G/:O5O@#\`-$_
M9Z\.77A3PYXX\4ZS97%SY\:^*=<:_DMV(PPCD=0X4\$J21GICG/SI^TQ^W-^
MUE^R%^SS=_MC_$[X7?#?Q/X'L=/LK[6O#OA+Q/=IJVFP37$,+_99Y8&@U9@)
M0P`6TRP"@MN!KZW\+>([7Q9X?L/$EE:W$$.HV,-W##=PF*9$D0.H=#RC`'!4
M]""*F%"G3=TOS!ML3Q3X7T+QCH-WX8\4:3;W^G7]L]O>V5W$'CFC88*LIX((
MKYKA_P""6O@/P-X@GUC]G7X[?$'X:6MY$!>:5X8UO=;RL-HWXG#L#A1G)/Y<
M5](^-(_%<WAN]@\"ZAI]IK#6S#3KG5;-[BVCE/1I(XY(W=1W"NI]Z^-OV<OV
MR_VX?CA^W3\:OV.M1O/A790?!-_#KZAK<'A34W?68]3M6N66-#J.+=HU0J"3
M("2#@`8+J4*51WDM03:V.YU#_@G-\1/$^C2>'O'/[?7Q>U.RN?EO[0:I#%'<
M1[\[#A"PR``<'GGCG%>O?L]?LI_!#]E_PZWASX.^"+?31.B"^OW)DNKQER0T
MLK?,W)8@?=&>`*]&5MPSCO7F?[:'QNUO]FC]D?XF?M$^&M'M-1U#P+X#U77K
M*POBPAN9;2TDG2-RA#!69`"00<=*F.'I0=T@;;/3:^/_``O_`,$C]!\`^.]6
M^(GPT_:H^(GAK4]8GG>\GT6>VA+++*96C)$7S*&Z9R>!SG).W^QC^U!^T7\>
M=2T.[^)=WI%O!>^'DU'5-.M/@UXDT=$=XU/EP:AJ4HAE"NX_Y9[G12P5>WU*
M#D9IU:%*LTYJ]M@3:V/FD_L%?%;M_P`%#_C-_P"#6V_^-5[_`."O#5SX0\+:
M=X;GUV]U62PLHX)-1U.<R7%TRJ`99&/5F.2>W/&!7D?[?_[;&@_L+?!W3OB7
MK'@RXUFXUSQ18>']*66X^QZ=:W5W,L23ZA?,K1V%JI.6F<'G:JJS,!73_!B_
M_:7U#5[C4_CEJ_P[BL+N*1M,T;P:M[<2P`2?(SWMPZ+<#8#G;;189L#(7EPH
MPIN\0O<],KP#X&?L`^!/@3^TCXH_:6T'QQK5]J?BG[=]JTZ]2#[/#]JN4N&V
M%$#\%`HR3P>:]_KY^_;T_;*UW]CFY^$=UI7P^N_$=IX_^*UKX5UBVTO3+B]O
MK>UFL;RX,]M!;Y>616MD)4*WR;R%)`ISI0G).2VU0)M;'T#17QOXJ_X*@ZJ/
M^"COP-_8N\$?"O5X-$^*&B^)+O7-8\9^#M6T6\M)-.M%GB6U6\AA68.20Y`;
M:-O(R,_9%:"."_:5^`NB_M+?!C6/@MXCUV[TVRUD0B>]L%0S1B.9)1MW@KR4
M`Y!ZU7_9=_9YT']EKX.:9\%_"^NWNIV6F37,D5[J(02N9IGE(.Q0O!<@8'05
MZ+167L::J<]M;6`*\E_;`_9,\+?MC?#>T^&'C'Q-J.D6EIK$6HI<:6L9D9TC
ME0*?,5AMQ*3TSP*]:KYG_8U_;=\;?M)?MB?M+_LV>)/!VE:?IWP/\5:)I6B:
MA8O(9]1CO;!KEWG#,54JR[1L`&.O/-5.$:D7&6P'KW[-_P`"]%_9L^#6B_!;
MP[K5WJ%EH<<J07E\$$LHDF>4[M@"Y!<C@#@5UGB'PUH?BS1+OPUXETJVO]/O
MK=X+VRNX%DBGC889&5L@@CL:O5\K_MO_`+;'[0?[./[1GPV^$'P,^`5C\08?
M$OA;Q'X@\0Z+'?M!JT]II9L`T.FDGR7N"+TN(YMJR>5L#*S`T*G%14>B`2Y_
MX)4?#+POX\N?'G[/?QB\;_#&2]C*WECX2U55MWSZ+*K%5ZX7.%S\N.E:3?\`
M!/#Q%KW_`!+_`(B?MM_&/7=+89DTY_$B6VYQRK>9#&&&#SC/-<S^S)_P5!M?
MVK_VY4_9Z^&?@`Q>!I?@J/&$?B/5(YK?4EU5-3CLKG2I[5POV:6W#KYJ/EPS
M+_"06^O:Q^J4%LBN:1S_`,-_`%K\,O`VF>`M-UO5-1M]*MA!!>ZU?FYNI4!.
M/,E89<@<9/8"O'OC;_P3Y\#?&OQSJOQ*NOC)\1M#UO5(HHQ-H?BN2&WMA$N(
MPD`&W:"6;:<C+L>]'[;?[<L7[)?B?X6?#G2_`D6L>(/BYXU/AOPY<ZOJ;:?I
M%E,L+3,]Y=K#,8BP4)$BQLTCG`P`2/0/@A<?'YM,EG_:!\0^"+F]NHHI+.T\
M&6-U'';<-YB-+<3.UP`2H601PYP24&0!I*C3E'E:T$FUL>1#]@?XW_VJSK_P
M44^+GV'[,%6'[;!YOG;L[M^S:4VX&W;G/.[M6Y\!_P#@F]^S[\#?'+_%F:+5
M/%GB^5Q/+XC\67:W4RW.27N(UVA8Y&)Y8#(P`"!G/T%45Q>06SHDLJJ7.$#,
M,L?0#O4+"T8N]OOU'S2):***Z"0(!ZBN.^.'P,^&_P"T3\.[[X8?%+P['?Z5
M?*"1G;+!*/N31/UCD4\AA].02#V-%3*,9Q:DKH#\Q/$'[/'[='_!,KXA:CXX
M_9C:\\6_#^:X,UQIPC-RK1@8Q=VT>&$BCY1/%Q@9.!A:]F^"/_!;']G#QGI=
MM:_&/2M4\'ZJ6*73+:O>68(0G>'B&\`D8VE,@D#G[U?:30(WKP<UX_\`%C]@
M?]D7XTYF\<_!+1C<F3>U]I<)L9V8L6;=);E&;)))SG.>:\_ZI7P[OAY:=GLO
M0MSC+<F7]O7]C)E#C]I_P4`PR,Z_"/YFN?\`B+_P4R_8E^'&CC5[GX[:3JS-
MGRK/PZYOIG(QQMBR%Z]7*@XX.>*\W;_@A_\`L=,Q8:]XX7)Z+KD.![?\>];'
M@K_@C3^Q3X1U3^U-1T+7_$&'1X[;7=;+1(5;/W85C#@]"K[@1VH<\R>G+%?-
MBM3[GAOQ<_X*Z?&GX[>+5^#W[#/PJO1=WLOE6^K7MH)[V3+!=\</,4"C/WY2
M0,Y(6N]_8?\`^"5\W@SQ3%^T/^UAJG_"0>-GNY+R+29YQ<P6L[-N6XF<C]_.
M#D_W%)&,E01];_#/X(?"7X,Z4=%^%/P[T?P_;,`)$TJP2(R`$D;V`W/@L<;B
M<5U*1JF=O>G2P4I252O+F?X+T\PYK;"H"%&[KCFEHHKT23SCXR_LE_L]?'_Q
M+HOC7XM_"O3=7UOP[#/#H6MDR07MA'.`LT<5Q"R2*C@`,N[:<=*W_AE\%_A/
M\&]/N-*^%/PST#PU;W4WG7<6A:1#:BXEVA?,D\M1YCD*H+-DG`YX%=110`5R
MOB_X+?"GQUX\\+_%+Q?\/M)U'Q)X+GN9O"FN75DK7.E/<0F"<PR?>021L58`
MX(QGH,=510`V/=L`88-4_$GAK0/&.@WGA;Q7HEGJ6F:A;/;ZAIVH6J3P7,+J
M5>.2-P5=&4D%2""#S5ZB@#RS2/V(_P!D7P]JUOK>B_LS^!89[*>.?3B/"]J4
MT^5"&#VR%"ELVX!R8@A9@&.6&:]3HHH`"`>HKD_#7P1^%7A'XF>(OC+X:^'^
MDZ?XJ\6VUI!XFUZTLU2YU-+576W$S#[_`):R.JD\@''0`5UE%`!6-\0_A]X.
M^*W@?5_AK\0_#UKJ^@Z]IL^GZSI5]%OAO+69"DL3KW5D)4CT)K9HH`\$^!__
M``3$_8)_9L^(=E\6/@3^ROX3\,>(]-CECL=7TNT9)H5DC,;A26(`*,R_0U[W
M110!G>+?"'A3Q]X<O/!_CCPUI^LZ3J$!AO\`2]5LH[BWN8SU22.0%77@<$$5
MP_PM_9'_`&:_@GXB?Q-\)O@;X9T"^9IC%=:9I,<36JRG,L<&!_H\;M\S1Q;$
M9B6*DDFO2:*`"N=\;?"GX??$K4_#^L>/?"-CJESX4UQ=8\.37D6YM/OEBDA6
MXCY^5Q'-*N?1S7144`<GK_P0^%'B?XI:%\;=?^'VDWOBWPSI]Y8^'O$-U:*]
MUIUO=;/M$<+GF,2>6@;')`QT)%=6N=HR,&EHH`****`"N5\#_!7X6?#/Q5XG
M\<^`/`.E:5K/C74XM0\6ZI8V:QSZK<QPK"DL[CF0K&BJ,\`9QR23U5%`!7.:
MS\)OAYK_`,1M%^+>L>#[*Y\2^';"[LM$UJ6+,]G!=&(W$:-V63R(=WKY:UT=
M%`'":%^S3\"?#GQQU7]I;0_A1H=GX^US1TTK6/%EM8JE[>V:LCK#+(,;P#&G
M)Y^11G"@#NZ**`,+XC?#+X=?%OPT_@SXI>`-%\2Z1+,DLFEZ_I4-[;,Z'<CF
M*960LIY!(X/(KEOA7^RA^SO\#M8EU_X0_!7PWX>O)A,IN=-TM$DB2:3S)(8F
MQF"%I/G,,>V/<2VW))KT:B@`KEO&OP9^%GQ%\5^'_''CGX<:)K&L>$[F2Y\,
MZIJ>FQSSZ7-(`'D@=P3$QVKRN#\H]!74T4`%%%%`!1110`4444GL`4444=0"
MBBBA;`%%%%,`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
BHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`/_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
